Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferences.
adherence
ixekizumab
preferences
psoriasis
satisfaction
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
22
09
2020
accepted:
15
10
2020
pubmed:
3
11
2020
medline:
25
5
2021
entrez:
2
11
2020
Statut:
ppublish
Résumé
Ixekizumab is a humanized monoclonal antibody that exhibits its immunomodulatory effects by binding to interleukin 17A (IL-17A), a proinflammatory cytokine. It was approved for the treatment of plaque psoriasis by the Food and Drug Administration in 2016. Ixekizumab has demonstrated superiority in clinical trials against etanercept, with no significant difference in the side effect profile. The chronicity of psoriasis requires continual treatment to achieve disease clearance. Many factors may affect adherence to treatment including patient satisfaction, patient preferences, medication cost, and medication side effects. Limited data on patient adherence, satisfaction, and preference exists in formal literature. Often, surrogate measures must be used to extrapolate information regarding these measures. In this narrative review, we describe patient adherence, satisfaction, and preferences via both direct and surrogate measures as they relate to ixekizumab treatment for moderate-to-severe plaque psoriasis.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Dermatologic Agents
0
ixekizumab
BTY153760O
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14486Subventions
Organisme : FDA HHS
Pays : United States
Organisme : FDA HHS
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87-97.
Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354. https://doi.org/10.1101/cshperspect.a015354.
Menter A, Gelfand JM, Connor C, et al. Joint AAD-NPF guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445-1486. https://doi.org/10.1016/j.jaad.2020.02.044.
Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297-2320. https://doi.org/10.3390/ijms18112297.
Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9(1):5-21. https://doi.org/10.1177/2040622317738910.
Preuss CV, Quick J. Ixekizumab. In: StatPearls, ed. Treasure Island (FL): StatPearls Publishing; 2020 http://www.ncbi.nlm.nih.gov/books/NBK431088/.
van Cranenburgh OD, de Korte J, Sprangers MAG, de Rie MA. Smets EMA. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol. 2013;169(2):398-405. https://doi.org/10.1111/bjd.12372.
Alcusky M, Lee S, Lau G, et al. Dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis. Dermatol Ther (Heidelb). 2017;7(4):463-483. https://doi.org/10.1007/s13555-017-0205-2.
Thorneloe RJ, Bundy C, Griffiths CEM, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. British J Dermatol. 2013;168(1):20-31. https://doi.org/10.1111/bjd.12039.
Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(s4):9-14. https://doi.org/10.1111/j.1468-3083.2011.04060.x.
Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357-2367. https://doi.org/10.2147/PPA.S117006.
Baiano R, Staskon F, Miller R. Psoriasis patients utilizing secukinumab, ixekizumab, or brodalumab - comparisons to prior biologic medication adherence levels, reasons for switching, and reported changes in disease symptoms. J Drug Assess. 2019;8(Suppl 1):3. https://doi.org/10.1080/21556660.2019.1658298.
Murage MJ, Gilligan AM, Tran O, et al. Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis. J Dermatolog Treat. 2019;1-8. https://doi.org/10.1080/09546634.2019.1690622.
Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J Am Acad Dermatol. 2020;82(4):927-935. https://doi.org/10.1016/j.jaad.2019.11.015.
Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or adalimumab. Patient Prefer Adherence. 2020;14:517-527.
Feldman SR, Zhao Y, Navaratnam P, Friedman HS, Lu J, Tran MH. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(3):201-209. https://doi.org/10.18553/jmcp.2015.21.3.201.
Mattila K, Leino M, Mustonen A, Koulu L, Tuominen R. Influence of psoriasis on work. Eur J Dermatol. 2013;23(2):208-211. https://doi.org/10.1684/ejd.2013.1969.
Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS ONE. 2012;7(12):e52935. https://doi.org/10.1371/journal.pone.0052935.
Schaarschmidt ML, Schmieder A, Umar N, Terris D, Goerdt S, Peitsch WK. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147(11):1285-1294.
Kromer C, Schaarschmidt ML, Schmieder A, Herr R, Goerdt S, Peitsch WK. Patient preferences for treatment of psoriasis with Biologicals: a discrete choice experiment. PLoS One. 2015;10(6):e0129120.
Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310:271-319.
Tada Y, Ishii K, Kimura J, Hanada K, Kawaguchi I. Patient preference for biologic treatments of psoriasis of Japan. J Dermatol. 2019;46:466-477.
Kivelevitch DN, Tahhan PV, Bourren P, Kogan NN, Gusis SE, Rodríguez EA. Self-medication and adherence to treatment in psoriasis. Int J Dermatol. 2012 Apr;51(4):416-419. https://doi.org/10.1111/j.1365-4632.2011.05037.
Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674-681. https://doi.org/10.1111/bjd.16050.
Johansson E, Nunez M, Svedbom A, Dilla T, Hartz S. Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain. Clinicoecon Outcomes Res. 2018;10:747-759.
Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the psoriasis area and severity index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859-866. https://doi.org/10.1016/j.jaad.2003.09.014.
Shelton SK, Bai SR, Jordan JK, Sheehan AH. Ixekizumab: a review of its use for the Management of Moderate to severe plaque psoriasis. Ann Pharmacother. 2019;53(3):276-284. https://doi.org/10.1177/1060028018799982.
ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT01474512, A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1) 2000 https://clinicaltrials.gov/ct2/show/NCT01474512
ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT01597245, A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) (UNCOVER-2), 2000, https://clinicaltrials.gov/ct2/show/NCT01597245
ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT01646177, A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (UNCOVER-3), 2000 https://clinicaltrials.gov/ct2/show/results/NCT01646177
Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123-131. https://doi.org/10.1136/annrheumdis-2019-215386.
Paul C, Griffiths CEM, van de Kerkhof PCM, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80(1):70-79.e3. https://doi.org/10.1016/j.jaad.2018.06.039.
Strober B, Leonardi C, Papp KA, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76:432-440.
World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization; 2003.
Cao Z, Carter C, Wilson KL, Schenkel B. Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis. J Dermatol Treatment. 2015;26(2):113-120. https://doi.org/10.3109/09546634.2014.883059.
Leonardi CL, Blauvelt A, Sofen HL, et al. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(9):1483-1490. https://doi.org/10.1111/jdv.14211.
Armstrong AW, Lynde CW, McBride SR, et al. Effect of Ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials. JAMA Dermatol. 2016;152(6):661-669. https://doi.org/10.1001/jamadermatol.2016.0269.
Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire-general health version in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R177. https://doi.org/10.1186/ar3141.
Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and Oral treatments for plaque psoriasis a meta-analysis. JAMA Dermatol. 2020;156(3):258-269.